Compounds for treatment of cancer
The present invention relates to a compound of formula XXII and a compound of formula 17ya, which are defined as anywhere in the specification, to a composition comprising the same, and to a method of using thereof in the treatment of various forms of cancer.
1. A method of treating, suppressing, reducing the severity, reducing the risk, or inhibiting cancer comprising administering a compound 17ya represented by the structure:
or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, to a subject having cancer under conditions effective to treat the cancer.
2. The method of claim 1 , wherein said cancer is selected from the group consisting of prostate cancer, drug-resistant prostate cancer, breast cancer, ovarian cancer, drug-resistant ovarian cancer, skin cancer, melanoma, drug-resistant melanoma, lung cancer, colon cancer, glioma, leukemia, lymphoma, renal cancer, CNS cancer, uterine cancer, drug-resistant uterine cancer, and combinations thereof.
3. The method of claim 2 , wherein said cancer is melanoma cancer.
4. The method of claim 2 , wherein said cancer is metastatic melanoma.
5. The method of claim 2 , wherein said cancer is prostate cancer.
6. The method of claim 5 , wherein said prostate cancer is drug-resistant prostate cancer.
7. The method of claim 2 , wherein said cancer is ovarian cancer.
8. The method of claim 7 , wherein said ovarian cancer is drug-resistant ovarian cancer.
9. The method of claim 2 , wherein said cancer is uterine cancer.
10. The method of claim 9 , wherein said uterine cancer is drug-resistant uterine cancer.
11. The method of claim 2 , wherein said cancer is lung cancer.
12. The method of claim 2 , wherein said cancer is colon cancer.
13. The method of claim 2 , wherein said administering is carried out in combination with another cancer therapy.
14. A method of treating a drug resistant tumor or tumors comprising administering a compound 17ya represented by the structure:
or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, to a subject suffering from cancer under conditions effective to treat the drug resistant tumor or tumors.
15. The method of claim 14 , wherein said tumor is a melanoma cancer tumor.
16. The method of claim 14 , wherein said tumor is a metastatic melanoma tumor.
17. The method of claim 14 , wherein said tumor is a prostate cancer tumor.
18. The method of claim 14 , wherein said tumor is an ovarian cancer tumor.
19. The method of claim 14 , wherein said tumor is an uterine tumor, breast cancer tumor or glioma tumor.
20. The method of claim 14 , wherein said administering is carried out in combination with another cancer therapy.
21. A method of destroying a cancerous cell comprising providing a compound 17ya represented by the structure:
or an N-oxide thereof, or a pharmaceutically acceptable salt thereof and contacting the cancerous cell with said compound under conditions effective to kill the cancer cell.
22. A method of inhibiting, preventing, or slowing the progress of vascularization of a tumor comprising administering a compound 17ya represented by the structure:
or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, to a subject having cancer under conditions effective to inhibit, prevent or slow the progress of vascularization of said tumor.
23. The method of claim 22 , wherein said tumor is selected from the group consisting of prostate cancer tumor, drug-resistant prostate cancer tumor, breast cancer tumor, glioma tumor, ovarian cancer tumor, drug-resistant ovarian cancer tumor, skin cancer tumor, melanoma tumor, drug-resistant melanoma tumor, lung cancer tumor, colon cancer tumor, lymphoma tumor, renal cancer tumor, CNS cancer tumor, uterine cancer tumor, drug-resistant uterine cancer tumor, and combinations thereof.
24. The method of claim 22 , wherein said method further inhibits, prevents, or slows the progress of vascularization of a metastatic tumor.
25. The method of claim 24 , wherein said tumor is selected from the group consisting of prostate cancer tumor, drug-resistant prostate cancer tumor, breast cancer tumor, glioma tumor, ovarian cancer tumor, drug-resistant ovarian cancer tumor, skin cancer tumor, melanoma tumor, drug-resistant melanoma tumor, lung cancer tumor, colon cancer tumor, leukemia tumor, lymphoma tumor, renal cancer tumor, CNS cancer tumor, uterine cancer tumor, drug-resistant uterine cancer tumor, and combinations thereof.